Sunday 18 October 2026
Export BJDX’s income statement to Excel — free account
Bluejay Diagnostics, Inc.
BJDX Healthcare Medical Devices
Bluejay Diagnostics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $249,000.00. In the quarter to June 2026, EPS grew 80.1% and free cash flow grew 20.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.75
0.03
−3.85%
Follow BJDX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | — | — | — | — |
P/S ratio |
— | — | — | 0.00 | — | — | — | — |
Altman Z-Score |
— | — | — | (0.90) | — | — | — | — |
P/FCF ratio |
— | — | — | 0.00 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | 2.32 | — | — | — | — |
P/Operating CF |
— | — | — | (2.54) | — | — | — | — |
P/B ratio |
— | — | — | 0.65 | — | — | — | — |
Price to Tangible BV |
— | — | — | 0.65 | — | — | — | — |
EV/Sales |
— | — | — | 0.00 | — | — | — | — |
EV/EBITDA |
— | — | — | 0.00 | — | — | — | — |
EV/Operating CF |
— | — | — | (0.28) | — | — | — | — |
EV/FCF |
— | — | — | (0.24) | — | — | — | — |
Quick Ratio |
4.61 | 5.31 | 1.25 | 6.17 | 29.89 | 0.49 | 0.17 | — |
Current Ratio |
4.88 | 6.05 | 1.82 | 7.19 | 32.42 | 0.57 | 0.52 | — |
Net Debt/EBITDA |
0.76 | 0.62 | 0.23 | 1.12 | 6.18 | 0.88 | (0.48) | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 87.76% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.27) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.88 | 0.37 | 0.84 | 0.83 | 1.25 | 0.44 | 2.06 | — |
Capex/Depreciation |
(1.02) | (1.54) | (0.90) | (3.91) | (0.16) | 0.00 | (0.04) | — |
Interest Coverage |
(8,691.25) | (8.71) | — | — | (8.79) | — | (31.19) | — |
| (117.02%) | (485.63%) | (137.90%) | (58.25%) | (43.13%) | 32.45% | 22.97% | — | |
| (99.42%) | (363.37%) | (108.25%) | (53.83%) | (30.96%) | (95.18%) | (178.90%) | — | |
ROIC |
(536.23%) | (313.88%) | (939.02%) | (408.30%) | (151.35%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(116.49%) | (373.81%) | (363.92%) | (81.69%) | (17.13%) | 353.03% | (241.12%) | — |
Average Days of Receivables |
— | — | — | 0.00 | — | — | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,667.55% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,094.18% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 173.90% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
— | — | — | 1.31 | — | — | — | — |
Graham Number |
— | — | — | 0.00 | — | — | — | — |
Earnings Yield |
— | — | — | (120.51%) | — | — | — | — |
Free Cash Flow Yield |
— | — | — | (119.40%) | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 415.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(13.48) | (170.76) | (11,877.00) | (12,902.67) | (14,556.00) | (5,087.00) | (16,901.00) | — |
Capex per Share |
(0.39) | (6.70) | (1,006.00) | (1,998.83) | (79.67) | 0.00 | (60.00) | — |
Free Cash Flow per Share |
(13.87) | (177.46) | (12,883.00) | (14,901.50) | (14,635.67) | (5,087.00) | (16,961.00) | — |
Cash per Share |
11.50 | 93.93 | 3,155.00 | 16,858.33 | 63,492.67 | 9,124.00 | 960.00 | — |
Shareholders Equity per Share |
13.31 | 125.10 | 4,135.43 | 19,235.50 | 67,939.00 | (42,062.00) | (29,324.00) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — |
Book value per Share |
13.31 | 125.10 | 4,135.43 | 19,235.50 | 67,939.00 | (42,062.00) | (29,324.00) | — |
Free Cash Flow |
(6.23) | (8.13) | (9.02) | (8.94) | (4.39) | (0.51) | (1.70) | — |
Working Capital |
4.34 | 4.09 | 1.45 | 10.15 | 20.02 | (0.79) | (0.28) | — |
Capital Expenditures |
(0.17) | (0.31) | (0.70) | (1.20) | (0.02) | — | (0.01) | — |
Net Current Asset Value |
4.32 | 3.97 | 1.25 | 9.81 | 20.02 | (4.67) | (3.55) | — |
EV/EBIT |
— | — | — | 0.00 | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 4.82 | 0.00 | — | 0.00 | — |
Price to Operating Income |
— | — | — | 0.00 | — | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.11 | 0.13 | 0.61 | 0.25 | 0.43 | 0.34 | 0.23 | — |
Cash ROIC |
(55.90%) | (81.02%) | (176.71%) | (41.29%) | (11.14%) | 15.44% | 83.47% | — |
Accounts Receivable Turnover |
— | — | — | 0.00 | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.43 | 0.43 | 0.78 | 0.71 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 1.51 | 1.37 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 1,159.76 | 741.02 | 871.58 | 74.28 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 197.15 | 315.23 | — |
Average Payables |
0.18 | 0.32 | 0.56 | 0.47 | 0.34 | 0.20 | 0.20 | — |
Average Inventory |
— | — | — | — | — | 0.10 | 0.10 | — |
Average Assets |
6.89 | 5.76 | 9.19 | 17.27 | 11.27 | 1.22 | 0.46 | — |
Average Common Equity |
5.85 | 4.31 | 7.22 | 15.96 | 8.09 | (3.57) | (3.57) | — |
Columns are period end dates